Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification
DOI10.2307/2531201zbMATH Open0654.62088OpenAlexW2007343138WikidataQ47205739 ScholiaQ47205739MaRDI QIDQ3800950FDOQ3800950
Authors: John M. Lachin, Mary A. Foulkes 
Publication date: 1986
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2531201
Recommendations
- Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials
- Sample-Size Formula for the Proportional-Hazards Regression Model
- Sample size and power for the weighted log‐rank test and Kaplan‐Meier based tests with allowance for nonproportional hazards
- Analysis of Factorial Survival Experiments
- A Method for Sequential Analysis of Survival Data with Nonproportional Hazards
noncompliancepowerlog-rank teststratificationsample sizeclinical trialloss to follow-upequality of survival distributionsprognostic covariates
Cited In (24)
- Optimal number of accrual groups and accrual group sizes in longitudinal trials with discrete-time survival endpoints
- Calculation of Sample Size in Survival Trials: The Impact of Informative Noncompliance
- GenTwoArmsTrialSize
- Designing a phase-III time-to-event clinical trial using a modified sample size formula and Poisson-Gamma model for subject accrual that accounts for the lag in site initiation using the PERT distribution
- Nonparametric Estimation of Duration of Accrual and Total Study Length for Clinical Trials
- Sample Size Determination in Clinical Trials with an Emphasis on Exponentially Distributed Responses
- Determining sample sizes for combined incident and prevalent cohort studies with and without follow-up
- Sample size calculation for two‐arm trials with time‐to‐event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions
- Optimal treatment allocation and study duration for trials with discrete-time survival endpoints
- Sample size determination in superiority or non-inferiority clinical trials with time-to-event data under exponential, Weibull and Gompertz distributions
- Planning the duration of a survival group sequential trial with a fixed follow-up time for all subjects
- Sample size calculations for noninferiority trials for time-to-event data using the concept of proportional time
- On lachin'S formulae for sample sizes of survival tests
- Design and monitoring of survival trials in complex scenarios
- Predicting study duration in clinical trials with a time-to-event endpoint
- Cost-efficient clinical studies with continuous time survival outcomes
- Sample-Size Formula for the Proportional-Hazards Regression Model
- Information and information fractions for design and sequential monitoring of clinical trials
- On the empirical choice of the time window for restricted mean survival time
- Sample size estimation for cancer randomized trials in the presence of heterogeneous populations
- Investigating Maximum Power Losses in Survival Studies with Nonstratified Randomization
- Heterogeneous treatment effects in stratified clinical trials with time‐to‐event endpoints
- Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials
- Sample Size Estimation for Survival Outcomes in Cluster‐Randomized Studies with Small Cluster Sizes
This page was built for publication: Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3800950)
